Previous 10 | Next 10 |
NeuroMetrix (NASDAQ: NURO ) -33% on Q4 results . More news on: NeuroMetrix, Inc., NIO Limited, Genprex, Inc., Stocks on the move, , Read more ...
Shares of Epizyme (NASDAQ: EPZM) are down 14.7% at 1:59 p.m. EST after the biotech gained Food and Drug Administration approval for Tazverik in patients with epithelioid sarcoma. You read that right, the FDA approved the drug and investors now think the company is worth less than it was y...
Gainers: Allied Healthcare Products (NASDAQ: AHPI ) +115% . More news on: Allied Healthcare Products, Inc., NanoViricides, Inc., Vaccinex, Inc., Stocks on the move, , Read more ...
Co-Diagnostics (NASDAQ: CODX ) -17% on launching equity offering. More news on: Co-Diagnostics, Inc., Discover Financial Services, Telefonaktiebolaget LM Ericsson (publ), , Stocks on the move, Read more ...
IVERIC bio (NASDAQ: ISEE ) initiated with Outperform rating and $15 (123% upside) price target at Cowen and Company. More news on: IVERIC bio, Inc., Matinas BioPharma Holdings, Inc., Pacira BioSciences, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Epizyme (NASDAQ: EPZM) secured an accelerated approval from the Food and Drug Administration for its sarcoma drug Tazverik. The drug was approved specifically for patients with metastatic or locally advanced epithelioid sarcoma who aren't eligible for surgery to completely remove the tumor. ...
Epizyme (NASDAQ: EPZM ) says the Food and Drug Administration granted accelerated approval of its Tazverik (tazemetostat) treatment for the patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma, a rare, slow-growing type of cancer. More news on: Epizyme...
First and Only EZH2 Inhibitor Approved by the U.S. Food and Drug Administration U.S. Commercial Launch Underway Company to Host Conference Call Tonight at 5:30 p.m. ET Epizyme, Inc . (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, today an...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Epizyme ( EPZM -6.5% ) has exercised its option to sell $50M more of its common stock to Royalty Pharma under its funding agreements announced in November 2019 under which the latter initially bought $100M of stock. More news on: Epizyme, Inc., Healthcare stocks news, Stocks on the m...
News, Short Squeeze, Breakout and More Instantly...
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...